BioSpace News Archive

Drug Development

resTORbio Halts Respiratory Program for RTB101 After Phase III Failure

The company halted the development of the drug RTB101 for respiratory disease but will continue to test it in other areas. Look at the reasons behind the halt.

November 15, 2019
·
3 min read
·
Mark Terry
Business

Bayer and Dewpoint Therapeutics Ink $100 Million Research Partnership

The research pact will leverage Dewpoint’s biomolecular condensates technology platform and Bayer’s small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.

November 15, 2019
·
3 min read
·
Mark Terry
Business

Opinion: Personalized Medicine Is The Solution To Modern Cancer Treatment

People deserve a personalized approach in cancer treatment that considers their unique genetic traits and the latest medical research — this methodology stands a significantly increased chance of pushing back against the disease.

November 15, 2019
·
4 min read
Career Advice

Cover Letter Strategy Checklist

If you’re planning a cover letter or have one ready to send, take a stroll through this list to ensure strategic optimization.

November 15, 2019
·
3 min read
·
Katharine Hansen, PhD
FDA

BeiGene Announces FDA Approval of Brukinsa for Mantle Cell Lymphoma

It is the first BeiGene-discovered drug to be approved.

November 15, 2019
·
3 min read
·
Mark Terry
Job Trends

FUJIFILM Expands Texas Holdings with New Gene Therapy Center

FUJIFILM Corporation will invest 13 billion yen (about $120 million) to expand the company’s gene therapy business and establish a new Gene Therapy Innovation Center adjacent to its current facility in College Station, Texas and add about 100 jobs.

November 15, 2019
·
2 min read
·
Alex Keown
BioCapital

Clinical Catch-Up: November 11-15

It was a busy week for clinical trial announcements. Here’s a look.

November 15, 2019
·
12 min read
·
Mark Terry
Deals

Roche to Acquire Fibrosis-Focused Promedior for Up to $1.4 Billion

Under the terms of the agreement, Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion based on the achievement of certain predetermined development, regulatory and commercial milestones.

November 15, 2019
·
3 min read
·
Alex Keown
FDA

FDA Approves Shionogi’s cUTI Medicine Following Positive Advisory Support

The U.S. Food and Drug Administration approved Shionogi’s Fetroja as a treatment for adult patients with complicated urinary tract infections caused by a number of Gram-negative microorganisms.

November 15, 2019
·
3 min read
·
Alex Keown
Biotech Beach

Envista To File Registration Statement In Connection With Danaher Exchange Offer Announcement

Envista Holdings Corporation (NYSE: NVST) announced it intends to file a Form S-4/S-1 Registration Statement today with the Securities and Exchange Commission (SEC) in connection with Danaher’s (NYSE: DHR) proposed offer to exchange shares of Envista common stock it owns for shares of Danaher common stock

November 15, 2019
·
4 min read